Dyadic International (DYAI) Net Income (2018 - 2026)
Dyadic International (DYAI) posted Net Income of -$1.9 million for Q1 2026, down 35.27% sequentially from -$1.4 million in Q4 2025, and up 3.66% YoY from -$1.9 million in Q1 2025.
Dyadic International (DYAI) Net Income (2018 - 2026) Analysis & Trends
Dyadic International has reported Net Income for 9 years, with the latest figure at -$1.9 million in Q1 2026.
- Quarterly Net Income rose 3.66% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.2 million (down 26.5% YoY) and the FY2025 annual result came in at -$25.9 million, down 12.28% from the prior year.
- Net Income declined to -$1.9 million in Q1 2026 per DYAI's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Net Income peaked at -$190216.0 in Q3 2024 and troughed at -$7.4 million in Q2 2022.
- A 5-year average of -$2.5 million and a median of -$2.0 million in 2025 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2025: Net Income surged 99.8% in 2022, then tumbled 924.01% in 2025.
- Over 5 years, Net Income stood at -$2.3 million in 2022, then grew by 8.03% to -$2.1 million in 2023, then rose by 23.67% to -$1.6 million in 2024, then advanced by 8.97% to -$1.4 million in 2025, then sank by 35.27% to -$1.9 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$1.9 million, -$1.4 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | -1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.95 Mn |
| Dec 31, 2025 | -1.44 Mn |
| Sep 30, 2025 | -1.95 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Mar 31, 2025 | -2.02 Mn |
| Dec 31, 2024 | -1.58 Mn |
| Sep 30, 2024 | -190,216.00 |
| Jun 30, 2024 | -1.92 Mn |
| Mar 31, 2024 | -2.06 Mn |
| Dec 31, 2023 | -2.07 Mn |
| Sep 30, 2023 | -1.61 Mn |
| Jun 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | -2.59 Mn |
| Dec 31, 2022 | -2.25 Mn |
| Sep 30, 2022 | -2.63 Mn |
| Jun 30, 2022 | -7.43 Mn |
| Mar 31, 2022 | -6.68 Mn |
| Dec 31, 2021 | -12.63 Mn |
| Sep 30, 2021 | -15.86 Mn |
| Jun 30, 2021 | -9.83 Mn |